scholarly article | Q13442814 |
P356 | DOI | 10.1111/J.1365-2036.2007.03415.X |
P698 | PubMed publication ID | 17697208 |
P50 | author | Marco Daperno | Q53242942 |
Gianmichele Meucci | Q57131104 | ||
Angelo Viscido | Q57692716 | ||
P2093 | author name string | Gasbarrini A | |
Orlando A | |||
Riegler G | |||
Annese V | |||
Cappello M | |||
Armuzzi A | |||
Biancone L | |||
Prantera C | |||
Sostegni R | |||
Kohn A | |||
Peralta S | |||
Marrollo M | |||
P433 | issue | 5 | |
P921 | main subject | ulcerative colitis | Q1477 |
P304 | page(s) | 747-756 | |
P577 | publication date | 2007-09-01 | |
P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
P1476 | title | Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up | |
P478 | volume | 26 |
Q37983558 | A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease |
Q33564081 | Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? |
Q84145760 | Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience |
Q38259532 | Biological therapy for ulcerative colitis: an update |
Q53122367 | Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. |
Q36541160 | Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis |
Q37245232 | Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists |
Q37414620 | Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands |
Q34883210 | Current and emerging drugs for the treatment of inflammatory bowel disease |
Q33586890 | Fulminant legionellosis in two patients treated with infliximab for Crohn's disease: case series and literature review |
Q26827444 | Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease |
Q37825016 | Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease |
Q38056807 | Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis |
Q33574857 | Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience |
Q36167512 | MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE. |
Q35100746 | Management of acute colitis and toxic megacolon |
Q26777729 | Medical Therapy of Active Ulcerative Colitis |
Q53339638 | Modulation of Th1/Th2 balance by infliximab rescues postoperative occurrence of small-intestinal inflammation associated with ulcerative colitis. |
Q26866940 | Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease |
Q38240881 | Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis |
Q91789026 | Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure |
Q42730491 | Recent advances in the management of distal ulcerative colitis |
Q26852581 | Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus |
Q26823221 | Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis |
Q30239077 | Review article: dose optimisation of infliximab for acute severe ulcerative colitis |
Q37189011 | Steroid-refractory severe ulcerative colitis: what are the available treatment options? |
Q38726448 | Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids |
Q61821109 | Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis |
Q37141131 | The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis |
Q28073443 | Update on medical and surgical options for patients with acute severe ulcerative colitis: What is new? |
Q35046196 | Usefulness of the cytomegalovirus antigenemia assay in patients with ulcerative colitis |
Search more.